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Background
A previously established Bayesian dosing tool for warfarin was found to produce biased maintenance dose predictions. In the following study we aimed to: (1) determine if the biased warfarin dose predictions previously observed could be replicated in a new cohort of patients from two different clinical settings; (2) explore the influence of CYP2C9 and VKORC1 genotype on the predictive performance of the Bayesian dosing tool; and (3) determine if the prior population used to develop the kinetic-pharmacodynamic (KPD) model underpinning the Bayesian dosing tool was sufficiently different from the test (posterior) population to account for the biased dose predictions.
Methods
The warfarin maintenance doses for 140 patients were predicted using the dosing tool and compared to the observed maintenance dose. The impact of genotype was assessed by predicting maintenance doses with prior parameter values known to be altered by genetic variability (e.g. EC50 for VKORC1 genotype). The prior population was evaluated by fitting the published kinetic-pharmacodynamic model, which underpins the Bayesian tool, to the observed data using NONMEM and comparing the model parameter estimates to published values.
INTRODUCTION
Warfarin is an anticoagulant used to treat and prevent blood clots in patients with deep vein thrombosis, pulmonary embolism and atrial fibrillation. It is a difficult drug to dose accurately and safely due to a narrow therapeutic range and a delay in the time course of anticoagulant response relative to dosing. Furthermore, the maintenance dose required to achieve therapeutic anticoagulation varies by upwards of 15 fold between patients. 1, 2 Anticoagulation is monitored during warfarin therapy using the international normalised ratio (INR). The target INR for most indications, including atrial fibrillation, is approximately 2.5 with a suggested therapeutic range of 2-3. Treatment is considered successful if the time that patients spend within the therapeutic range (TTR) is maximised. Conventional, heuristic, dosing methods have been found to result in a TTR of only 40-60%. [3] [4] [5] [6] There have been a large number of publications exploring strategies to improve INR control and to predict warfarin dose requirements. A variety of nomograms, computerised decision-support tools and Bayesian prediction tools have been proposed to aid dosing decisions in the clinic. [7] [8] [9] [10] In the past ten years, more than 30 warfarin dosing algorithms have been published. 11, 12 
METHODS

Patient data
The 
Maintenance dose predictions
Details of the development of the Bayesian dosing tool (TCIWorks) have been published previously. 33 The underpinning model that describes the warfarin dose and anticoagulant response was a KPD model developed by
Hamberg et al. 34 Briefly, a KPD model is a pharmacokinetic-pharmacodynamic model where the pharmacokinetic The full dosing history for each patient from initiation to a stable INR, age, and all available INR observations up to the final dose change were entered into the Bayesian dosing tool. The Bayesian dosing tool was then used to predict the daily dose required to achieve the observed stable INR for each patient. The patients were assumed to be taking their prescribed dose at 6 pm and INR was assumed to be sampled at 10 am. The effects of concomitant drugs on warfarin INR response would be captured by the INR measurement itself and therefore was not accounted for a priori.
The predictive performance of the Bayesian dosing tool
The predicted maintenance doses were compared to the observed maintenance doses using measures of bias (mean 
,
where is the mean prediction error, is the number of patients, is the prediction error (predicted minus observed maintenance dose) of the th individual. No statistical bias was concluded if the 95% confidence interval (CI) of the included zero. is the average of the sum of squared differences between predicted minus observed maintenance dose, and is the square root of . provides an estimate of the variability of the prediction errors given in approximately the same units of the data (mg/day).
We stratified the dataset by observed maintenance dose into two groups; those who required ≥ 7 mg/day and those who required < 7 mg/day. A cut off of 7 mg/day has been used in other studies 1, 35 to categorize patients requiring a "high" daily dose and therefore was used here. and were assessed as above for each dose group.
The impact of genotype on the predictive performance of the Bayesian dosing tool
The influence of genotype on warfarin dose predictions was assessed by stratifying the study cohort into different 
The impact of the prior population on predictive performance of the Bayesian dosing tool
We explored the hypothesis that the bias may be caused by inherent differences in warfarin dose-response within our study population compared to the population used to develop the KPD model by Hamberg et al. 34 To address this, we fitted the published KPD model to our dataset using a nonlinear mixed effects modelling methodology in 34 A non-parametric bootstrap was carried out to assess the precision of the parameter estimates. A total of 1000 bootstrap datasets were generated by randomly sampling the original dataset and simulated from the model to obtain the 95% CI of each parameter estimate. The mean and 95% CI of the estimated model parameters from our study cohort were compared to the values from the published KPD model and considered not significantly different if the means were within 20% of the published values and confidence intervals overlapped with the published 95% CI. 
RESULTS
Thirteen
The predictive performance of the Bayesian dosing tool
A summary of the and results for each dataset analyzed separately and combined is presented in 
The impact of genotype on the predictive performance of the Bayesian dosing tool
Dose predictions for patients with the VKORC1 GG genotype were found to be positively biased but dose predictions for patients with VKORC1 AG and AA were unbiased (see Table 2 ). Similarly, dose predictions for patients with CYP2C9 *1*1 were positively biased in the combined dataset.
To explore the influence of genotype further, we compared the for patients with VKORC1 GG genotype who had CYP2C9 *1*1 and those who were not CYP2C9 *1*1 and found a positive bias for both combinations.
However, when we grouped patients with CYP2C9 *1*1 patients who were not VKORC1 GG, we found that dose predictions were not biased. This suggests that the source of the bias is more likely to be VKORC1 genotype.
Visual plots of the observed versus prediction maintenance dose according to VKORC1 and CYP2C9 are presented in Figures 1 and 2 , respectively.
The Bayesian dose predictions conducted using individual values of EC50 for each patient, corresponding to their observed genotype, were found to produce positively biased results overall (see Table 3 ). It is noteworthy that those subjects with reduced EC50 values (i.e. VKORC1 AG and AA genotypes) had unbiased dose predictions.
The for the VKORC1 GG genotype group remained the same since the wild-type values were used previously.
The impact of the prior population on the predictive performance of the Bayesian dosing tool
The results of the estimated parameters and bootstrap runs using the model to estimate into a new population are summarized in Table 4 . 93.8% of the bootstrap runs minimized successfully. Several mean parameter estimates were above the 20% criterion, however, mean parameter estimates for the more important parameters, such as EC50 for G allele and EC50 for A allele and between subject variability for EC50,were within 20%. The 95% CI for all the parameters estimated from the test population overlapped with the published model, except the population value for MTT1 (mean transit time). This parameter is not considered likely to be a cause of bias in predictions.
DISCUSSION
In this study, we have explored the possible causes of bias in warfarin maintenance dose predictions with a Bayesian dosing tool. A previously reported over-prediction of warfarin maintenance dose requirements was successfully replicated using two datasets from different clinical centres. Furthermore, dose predictions were carried out in the Bayesian system using all available INR measurements for each patient which should provide the most accurate estimate of the patient's response. The biased warfarin dose predictions were only observed in patients requiring ≥7 mg/day.
Several publications on the application of Bayesian methodologies to warfarin dose individualisation have been reported previously. 9, 10, 27, 36-38 A summary of previous Bayesian dosing tools for warfarin and how they differ from the dosing tool in our study have also been reviewed. 26, 33 Vadher et al 9 compared the observed dose to the predicted maintenance dose and found that their Bayesian dosing tool was negatively biased on average. A scatter plot of the observed dose versus predicted dose reported by Vadher et al 9 also showed biased predictions in patients requiring higher daily doses, although in a different direction (under-prediction in higher dose patients).
Other publications on Bayesian dosing tools for warfarin did not analyse the predictive performance of the dosing tool in a way that would allow comparison with our work.
Two possible explanations for the bias were explored in this study. First, we explored the hypothesis that the bias may be due to the influence of VKORC1 or CYP2C9 genotype. We focused primarily on VKORC1 since it was identified as a candidate in previous work 11 but in the present study it was found to have a relatively minor influence on dose predictions. In addition, the direction of dose prediction error (i.e. over or under-predicted dose)
in each patient requiring ≥ 7 mg/day was the same despite changing the EC50 priors to the values as per published prior model. This suggests that differences in EC50 prior parameter estimates (and hence influence of VKORC1)
does not have significant influence on the overall dose predictions and therefore does not explain the observed bias. Furthermore, the initial apparent association of bias and VKORC1 GG may be explained by a higher proportion of patients with VKORC1 GG in this dose category and therefore, the initial link between VKORC1
GG and bias was more likely to be an association rather than a cause. We also explored the possibility that the population used to derive the prior population parameter estimate for the KPD model had a different dose-response to our study population which would mean that the model could not be extrapolated to our study population. Our results suggest that the prior and posterior populations were not sufficiently different to be a plausible cause of the observed bias.
As noted above, the bias in warfarin dose predictions was evident only for those patients taking ≥ 7 mg/day. The reason for this is not currently clear. Since we have found that it is not likely to be the parameter values used as the basis of the prior, then this suggests it could be the structure of the prior model. We know the coagulation network is exceedingly complex. 39 We therefore feel it is plausible that the application of a single Emax model when used across a large range of dose-response values (as seen here) may not be sufficiently flexible to account for the inherent feedback and feedforward mechanisms of the coagulation network, which may be more apparent in those patients taking higher than average warfarin doses. A further exploration of this hypothesis is beyond the scope of the current work.
Although an accurate method for predicting the maintenance dose of warfarin intuitively should improve clinical outcomes, this can only be proven in clinical trials. Importantly, whether the observed bias in warfarin dose predictions might result in altered clinical outcomes cannot be explored in this study. Exploring a non-parametric approach to population modelling and Bayesian forecasting was beyond the scope of the current study.
CONCLUSION
In two patient cohorts, the Bayesian dosing tool resulted in positively biased warfarin dose predictions. Warfarin doses were over-predicted for patients requiring ≥ 7 mg/day by 1.15 mg/day on average. The bias was not found to be due to the influence of VKORC1 genotype, nor to differences in the prior and posterior populations. We conclude that there is a need for a more mechanistic dose-response model for warfarin that is capable of capturing the complexities of the coagulation network at higher warfarin doses. 
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